modelApomorphine

Diagram of Apomorphine

Extends from Pharmacolibrary.Drugs.ATC.G.G04BE07.

Information

name:Apomorphine
ATC code:G04BE07
route:subcutaneous
compartments:2
dosage:3mg
volume of distribution:2.3L
clearance:60L/h
other parameters in model implementation

Apomorphine is a non-ergoline dopamine agonist used primarily in the treatment of motor fluctuations ('off' episodes) in Parkinson's disease. It is administered as a rescue medication for rapid symptom relief. It is approved for subcutaneous use and is not typically administered orally due to extensive first-pass metabolism and very low oral bioavailability.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers following subcutaneous administration.

References

  1. Agbo, F, et al., & Navia, B (2021). Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease. Clinical and translational science 14(4) 1464–1475. DOI:10.1111/cts.13008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33650272

  2. Neef, C, & van Laar, T (1999). Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clinical pharmacokinetics 37(3) 257–271. DOI:10.2165/00003088-199937030-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10511920

  3. Briganti, A, et al., & Montorsi, F (2006). A comparative review of apomorphine formulations for erectile dysfunction : recommendations for use in the elderly. Drugs & aging 23(4) 309–319. DOI:10.2165/00002512-200623040-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16732690

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)